Evidence map›Paper›PMID 28958896›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease.

Scott S Graves, Maura H Parker, Diane Stone, George E Sale, Smitha P S Pillai, Melissa M Johnson, Rainer Storb

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Canine Hematopoietic Cell Transplantation for Graft-Versus-Host Disease.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Scott S GravesTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Maura H ParkerTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Diane StoneTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
George E SaleTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pathology, University of Washington School of Medicine, Seattle, Washington.
Smitha P S PillaiTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Melissa M JohnsonTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Rainer StorbTransplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington. Electronic address: rstorb@fredhutch.org.
Fred Hutch Cancer Center · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
NCI NIH HHS P01 CA078902NCI NIH HHS P30 CA015704NIDDK NIH HHS U54 DK106829
6 · The paper itself

Abstract

In murine model systems inducible costimulator (ICOS) signaling has been implicated in the formation of chronic graft-versus-host disease (GVHD). Previously, we showed that chronic GVHD can be reproducibly produced in the dog hematopoietic cell transplantation (HCT) model and that ICOS expression is upregulated on T cells in dogs with chronic GVHD. The goal of the present study was to determine whether administration of a short course of anti-canine ICOS mAb could alter the rapid and progressive course of chronic GVHD. Five dogs underwent HCT from dog leukocyte antigen mismatched unrelated donors after total body irradiation. Postgrafting immunosuppression consisted of methotrexate (days 1, 3, 6, and 11) and cyclosporine (days -1 through 78). Anti-ICOS mAb (3 injections, 72 hours apart) was administered upon diagnosis of GVHD. One dog failed to respond to anti-ICOS mAb therapy and succumbed to chronic GVHD in a time course similar to control untreated dogs. Overall, anti-ICOS-treated dogs experienced a significant prolongation in survival from the time of diagnosis of chronic GVHD compared with control dogs. Within the limitations of the number of study dogs we suggest that a short course of anti-ICOS mAb may be useful in the treatment of chronic canine GVHD.

Indexed as

AnimalsAntibodies, MonoclonalAntigens, SurfaceDisease Models, AnimalDogsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunosuppression TherapyInducible T-Cell Co-Stimulator ProteinSurvival RateTreatment OutcomeAntibodies, MonoclonalAntigens, SurfaceInducible T-Cell Co-Stimulator ProteinAnti-ICOSCanineGVHDHCT

Identifiers

PMID28958896
PMCPMC5743626
OpenAlexW2759053808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.